Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics will present a late-breaking poster on inhaled LTI-03 in idiopathic pulmonary fibrosis at the European Respiratory Society 2026 Congress in Barcelona, running September 5-9, 2026. The poster (PA6217, September 8 session on immunological mechanisms in pulmonary fibrosis) will be presented by Professor Philip Molyneaux of Imperial College London, and the underlying data has already been published in Nature Communications. LTI-03 is a first-in-class inhaled peptide therapy derived from Caveolin-1 biology with U.S. Orphan Drug and Fast Track designations, and it is being tested in the randomized, placebo-controlled Phase 2 RENEW trial (NCT06968845).
Key figures
- Drug Name
- LTI-03
- Phase Of Trial
- Phase 2
- Nct id
- NCT06968845
- Conference
- European Respiratory Society (ERS) 2026 Congress
- Trial name
- RENEW
- Trial design
- randomized, placebo-controlled, two dose levels vs placebo
- Poster number
- PA6217
- Primary endpoint
- safety (treatment-emergent adverse events through Week 24)
- Efficacy endpoint
- change from baseline in forced vital capacity (FVC)
- Presentation date
- September 8, 2026
- Planned enrollment
- 120
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.